Pinnacle Financial Partners Inc. Boosts Holdings in AbbVie Inc. (NYSE:ABBV)

Leslie Hanson
November 13, 2017

Northeast Investment Management reduced its stake in shares of AbbVie Inc. The Eagle Ridge Investment Management holds 108,728 shares with $6.85 million value, up from 96,894 last quarter. Trading volume for AbbVie Inc. was 6.17 Million in its previous trading session. The stock decreased 0.35% or $0.19 on November 10, reaching $53.81. $5.59M worth of AbbVie Inc (NYSE:ABBV) shares were sold by Schumacher Laura J. On Wednesday, June 14 ALBAN CARLOS sold $3.21 million worth of AbbVie Inc (NYSE:ABBV) or 45,800 shares.

AbbVie Inc. (NYSE:ABBV) touched its 1-Year High price of $98.26 on 10/20/17 and its 1-Year Low price of $58.60 on 11/23/16. It has underperformed by 6.07% the S&P500. That suggests something of the likelihood of a short squeeze in shares of ABBV. Its down 11.06% from 14.21 million shares, reported previously. The SI to Biotime Incorporated's float is 10.61%.

Woodmont Investment Counsel Llc, which manages about $557.42M and $354.44M US Long portfolio, upped its stake in General Electric Co (NYSE:GE) by 16,901 shares to 175,175 shares, valued at $4.73 million in 2017Q2, according to the filing. Hill International Inc (HIL) has risen 22.81% since November 11, 2016 and is uptrending.

Since May 18, 2017, it had 0 insider buys, and 4 insider sales for $15.96 million activity. Bollard Group LLC now owns 3,764 shares of the company's stock worth $273,000 after acquiring an additional 19 shares in the last quarter. 143,325 were reported by Skba Cap Ltd. Arcadia Mgmt Mi holds 2.16% of its portfolio in AbbVie Inc (NYSE:ABBV) for 93,901 shares.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. First PREMIER Bank now owns 1,950 shares of the company's stock valued at $123,000 after buying an additional 1,850 shares in the last quarter. Jfs Wealth Llc owns 1,131 shares.

Investors sentiment decreased to 0.79 in Q2 2017. Its up 0.01, from 0.99 in 2017Q1. It increased, as 55 investors sold ABBV shares while 581 reduced holdings. Cadence Capital Lc has invested 0.91% in AbbVie Inc (NYSE:ABBV). American Rech Mgmt Communication holds 0.99% or 111,862 shares in its portfolio. 106,067 were reported by Gillespie Robinson & Grimm Incorporated.

AbbVie a research-based biopharmaceutical company. Marietta Investment Prtn Ltd Liability reported 0.76% of its portfolio in AbbVie Inc (NYSE:ABBV). AbbVie makes up about 1.1% of Pinnacle Financial Partners Inc.'s portfolio, making the stock its 17th largest position. The Iowa-based United Fire Group Inc has invested 5.01% in Wells Fargo & Co (NYSE:WFC). Conestoga Limited Com holds 7,935 shares. St. Louis Trust Co boosted its stake in AbbVie by 0.7% during the second quarter. Jolley Asset has invested 0.95% in AbbVie Inc (NYSE:ABBV). AbbVie Inc. The stock has a 50 day moving average of $60.31 and a 200 day moving average of $62.69. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company's stock. Therefore 42% are positive. Capital Product Partners L.P. had 12 analyst reports since August 25, 2015 according to SRatingsIntel. Citigroup upgraded it to " rating and $60 target in Monday, September 28 report. The stock of AbbVie Inc (NYSE:ABBV) earned "Hold" rating by Deutsche Bank on Tuesday, March 15. The stock has "Buy" rating by Jefferies on Thursday, May 25. Finally, BMO Capital Markets reiterated a "hold" rating and issued a $66.00 target price on shares of AbbVie in a report on Thursday, September 28th. BMO Capital Markets maintained it with "Hold" rating and $63 target in Wednesday, April 19 report. The firm earned "Neutral" rating on Thursday, September 8 by JP Morgan. The rating was upgraded by Jefferies to "Buy" on Monday, December 7. William Blair reiterated an "outperform" rating and set a $76.00 price objective on shares of AbbVie in a research note on Thursday, December 8th. The firm has "Outperform" rating given on Monday, November 30 by RBC Capital Markets.

BioTime, a clinical-stage biotechnology firm focused on developing and commercializing products addressing degenerative diseases. The company has a market capitalization of $152,347.31, a price-to-earnings ratio of 17.97, a PEG ratio of 1.32 and a beta of 1.51. The Company's clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. It has a 23.06 P/E ratio. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Investors sentiment decreased to 0.79 in Q2 2017. Its up 0.12, from 0.76 in 2017Q1. It also reduced Cisco Systems Inc. The company reported $1.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.39 by $0.02. Quantitative Limited Liability Corp accumulated 750,800 shares or 0.82% of the stock.

Roffman Miller Associates Inc decreased Under Armour Inc Class A (UA) stake by 28.51% reported in 2017Q2 SEC filing. Cap World holds 0.06% or 3.43 million shares in its portfolio. Moreover, State Street has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX). Granite Point Mngmt L P invested in 44,550 shares. Evanson Asset Mngmt Ltd Company invested in 0.18% or 10,637 shares. Shaker Financial Services Llc, a Virginia-based fund reported 29,890 shares. Moreover, Rutabaga Capital Management Llc Ma has 1.65% invested in the company for 1.70 million shares. Berson And Corrado Inv Limited Liability Company accumulated 61,875 shares or 0.11% of the stock. Usa Portformulas holds 0.1% or 5,887 shares in its portfolio.

Other reports by Iphone Fresh

Discuss This Article